{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:38:55Z","timestamp":1790005135488,"version":"4.0.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,1,2]]},"DOI":"10.1097\/qad.0b013e328317a702","type":"journal-article","created":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T03:14:33Z","timestamp":1228101273000},"page":"83-87","source":"Crossref","is-referenced-by-count":101,"title":["Low atazanavir concentrations in cerebrospinal fluid"],"prefix":"10.1097","volume":"23","author":[{"given":"Brookie M","family":"Best","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott L","family":"Letendre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Brigid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B","family":"Clifford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann C","family":"Collier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin B","family":"Gelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin C","family":"McArthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Allen","family":"McCutchan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund V","family":"Capparelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(02)09411-4","article-title":"Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies","volume":"360","author":"Egger","year":"2002","journal-title":"Lancet"},{"key":"R2-11-20210130","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/QAD.0b013e328133f285","article-title":"Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies","volume":"21","author":"May","year":"2007","journal-title":"AIDS"},{"key":"R3-11-20210130","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(06)69152-6","article-title":"HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis","volume":"368","author":"May","year":"2006","journal-title":"Lancet"},{"key":"R4-11-20210130","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1176\/jnp.15.2.208","article-title":"Longitudinal improvement in psychomotor processing speed is associated with potent combination antiretroviral therapy in HIV-1 infection","volume":"15","author":"Ferrando","year":"2003","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R5-11-20210130","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1055\/s-2006-956759","article-title":"Dementia and neurocognitive disorders due to HIV-1 infection","volume":"27","author":"Ances","year":"2007","journal-title":"Semin Neurol"},{"key":"R6-11-20210130","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ana.10827","article-title":"Changing incidence of central nervous system diseases in the EuroSIDA cohort","volume":"55","author":"d'Arminio Monforte","year":"2004","journal-title":"Ann Neurol"},{"key":"R7-11-20210130","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1080\/13550280290049615","article-title":"HIV-associated cognitive impairment before and after the advent of combination therapy","volume":"8","author":"Sacktor","year":"2002","journal-title":"J Neurovirol"},{"key":"R8-11-20210130","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1212\/WNL.54.4.927","article-title":"Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources","volume":"54","author":"Ellis","year":"2000","journal-title":"Neurology"},{"key":"R9-11-20210130","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1212\/WNL.61.10.1391","article-title":"Two phases of HIV RNA decay in CSF during initial days of multidrug therapy","volume":"61","author":"Haas","year":"2003","journal-title":"Neurology"},{"key":"R10-11-20210130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/088922203763315669","article-title":"Roundtable report: importance of antiretroviral drug concentrations in sanctuary sites and viral reservoirs","volume":"19","author":"Reddy","year":"2003","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R11-11-20210130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00042560-199901010-00006","article-title":"Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1\u2013 infected patients with and without AIDS dementia complex","volume":"20","author":"Aweeka","year":"1999","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"R12-11-20210130","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1067\/mcp.2000.109391","article-title":"Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection","volume":"68","author":"Haas","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"R13-11-20210130","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/00042560-199908150-00003","article-title":"Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir","volume":"21","author":"Kravcik","year":"1999","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R14-11-20210130","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1128\/AAC.44.8.2173-2175.2000","article-title":"Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center Group","volume":"44","author":"Letendre","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"R15-11-20210130","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/S0140-6736(05)63640-9","article-title":"Indinavir in cerebrospinal fluid of HIV-1-infected patients","volume":"350","author":"Stahle","year":"1997","journal-title":"Lancet"},{"key":"R17-11-20210130","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/QAD.0b013e32814e6b1c","article-title":"The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial","volume":"21","author":"Vernazza","year":"2007","journal-title":"AIDS"},{"key":"R19-11-20210130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archneurol.2007.31","article-title":"Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system","volume":"65","author":"Letendre","year":"2008","journal-title":"Arch Neurol"},{"key":"R20-11-20210130","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1128\/AAC.00098-06","article-title":"Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection","volume":"50","author":"Colombo","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-11-20210130","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1128\/AAC.00761-07","article-title":"Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection","volume":"52","author":"Kiser","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R22-11-20210130","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1086\/319281","article-title":"Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable","volume":"183","author":"Drusano","year":"2001","journal-title":"J Infect Dis"},{"key":"R23-11-20210130","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/01.aids.0000171409.38490.48","article-title":"Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV","volume":"19","author":"Capparelli","year":"2005","journal-title":"AIDS"},{"key":"R24-11-20210130","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1086\/523002","article-title":"Lopinavir with ritonavir reduces the HIV RNA level in cerebrospinal fluid","volume":"45","author":"Letendre","year":"2007","journal-title":"Clin Infect Dis"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002030-200901020-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T03:07:16Z","timestamp":1618024036000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-200901020-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,2]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e328317a702","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1141987.599103","asserted-by":"object"}]},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1,2]]}}}